Tranexamic Acid News and Research

RSS

Using zebrafish to discover and identify new drugs to treat spinal cord lesions

A research team led by Leonor Saúde, Principal Investigator at Instituto de Medicina Molecular, in partnership with the company Technophage, SA, has designed a simple and efficient platform that uses zebrafish to discover and identify new drugs to treat spinal cord lesions.

22 Jul 2019

Blocking activity of plasma protein can be possible way to protect against radiation-induced injury

It is possible to prevent certain injuries that can occur in radiation therapy against cancer. By blocking the activity of a plasma protein during and immediately after radiation, the patient can be protected against injury. This is shown in a new doctoral thesis at Umeå University, Sweden.

20 Nov 2018

Blood management program associated with fewer transfusions in orthopedic patients

A patient blood management program designed to limit the amount of transfused blood orthopedic patients undergoing common surgeries such as hip and knee replacement receive was associated with fewer transfusions, reduced blood use and improved outcomes, reports a study published in the Online First edition of Anesthesiology, the peer-reviewed journal of the American Society of Anesthesiologists.

20 Aug 2018

Study: Drug used to treat blood loss may be beneficial for some stroke patients

Patients with stroke caused by bleeding on the brain may benefit from receiving a drug currently used to treat blood loss from major trauma and bleeding after childbirth, an international trial has revealed.

16 May 2018

Low-cost drug could prevent postpartum hemorrhage after vaginal delivery

Postpartum hemorrhage (major blood loss after labor and birth) is the leading cause of maternal mortality worldwide, accounting for approximately one-quarter of all maternal deaths.

29 Jan 2018

Low-cost drug for severe bleeding could save lives of mothers after childbirth

An inexpensive and widely available drug could save the lives of one in three mothers who would otherwise bleed to death after childbirth, according to a major study published in The Lancet. The global trial of 20,000 women found that death due to bleeding was reduced by 31% if the treatment was given within three hours.

29 Apr 2017

AAOS issues new guidelines for treatment of hip osteoarthritis

The American Academy of Orthopaedic Surgeons recently released a new clinical practice guideline on the treatment of osteoarthritis of the hip that strongly recommends the use of pre-surgical treatments to ease pain and improve mobility, including corticosteroid injections, physical therapy and non-narcotic medications.

11 Apr 2017

Simple saline solution could help alleviate chronic nosebleeds, study shows

Squirting a simple saline solution into the nose twice a day could alleviate chronic nosebleeds just as effectively as spraying with any one of three different medications, reports a study published online in the Journal of the American Medical Association on Sept. 6.

7 Sep 2016

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding.

6 Sep 2016

New guidance for administering hemorrhage prevention treatment

Tranexamic acid (TXA) is currently being administered to injured patients by many prehospital air and ground systems, despite a lack of evidence supporting or refuting its efficacy in preventing hemorrhage. Several studies examining prehospital use of TXA are currently in progress, but until now there have been no guidelines for healthcare professionals administering TXA to patients.

26 Aug 2016

New guidance provides effective practices for prehospital use of TXA in injured patients

16 Aug 2016

Administering TXA through IV and IA can reduce blood loss following total knee replacement

A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).

22 May 2016

TXA drug reduces blood transfusion, saves costs

Using an inexpensive drug for every hip or knee replacement since 2013 has helped St. Michael's Hospital reduce its number of red blood cell transfusions performed during these surgeries by more than 40 per cent without negatively affecting patients, according to new research.

4 Sep 2015

Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

Haemonetics Corporation today reported revenue for the fourth quarter fiscal 2015 of $226.5 million, down 6%. Excluding currency impact, revenue was down 4% in the quarter. The Company reported a fourth quarter GAAP net loss of $2.9 million or $0.06 per share.

27 Apr 2015

Alternative treatment options for uterine fibroids

A 47-year-old African-American woman has heavy menstrual bleeding and iron-deficiency anemia. She reports the frequent need to urinate during the night and throughout the day. A colonoscopy is negative and an ultrasonography shows a modestly enlarged uterus with three uterine fibroids, noncancerous growths of the uterus.

24 Apr 2015

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

Haemonetics net revenue increases 8% to $235.8 million in Q2 fiscal 2014

Haemonetics Corporation today reported second quarter fiscal 2014 net revenue of $235.8 million, up 8%, GAAP net income of $16.5 million and earnings per share of $0.32. Adjusted net income, exclusive of transformation, integration and deal amortization expenses detailed below, was $34.4 million, up 24%, and adjusted earnings per share were $0.66, up 24%. Excluding currency impact, net revenue was up 11% in the quarter.

28 Oct 2013

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.

11 Jul 2013

University of Nottingham to study use of tranexamic acid in people with intracerebral haemorrhage

Scientists in Nottingham are leading an international study to investigate the effectiveness of a new treatment on a devastating type of stroke.

19 Mar 2013

NHS intravenous (IV) fluids: an interview with Dr Ian Roberts, LSHTM

Saline is just salty water, whereas colloids are solutions that have large molecules in them. In this case, the molecules are starch. The idea is that because these molecules are big they don’t leak out of the circulation as much.

18 Mar 2013